北京万泰生物药业股份有限公司 章 程 二〇二四年十月 | 录 | | --- | | 目 | | 第一章 | 总 则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股 份 | 2 | | 第一节 | 股份发行 2 | | | 第二节 | 股份增减和回购 4 | | | 第三节 | 股份转让 5 | | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 6 | | | 第二节 | 股东大会的一般规定 8 | | | 第三节 | 股东大会的召集 12 | | | 第四节 | 股东大会的提案与通知 13 | | | 第五节 | 股东大会的召开 15 | | | 第六节 | 股东大会的表决和决议 17 | | | 第五章 | 董事会 | 20 | | 第一节 | 董事 20 | | | 第二节 | 董事会 23 | | | 第六章 | 总经理及其他高级管理人员 | 27 | | 第七章 | 监事会 | 29 | | 第一节 | 监事 29 | | | 第二节 | 监事会 29 | | | 第八章 | 财务会计制度、利润分配和审计 | 3 ...

北京万泰生物药业股份有限公司 董事、监事和高级管理人员所持公司股份及其变动管理制度 北京万泰生物药业股份有限公司 董事、监事和高级管理人员所持公司股 份及其变动管理制度 董事、监事和高级管理人员所持公司股份及其变动管理制度 （2024 年 10 月修订） 第一章 总则 第一条 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司董事、监 事和高级管理人员所持本公司股份及其变动管理规则》等法律、法规、规范性文 件以及《公司章程》的有关规定，结合公司实际情况，制定本制度。 第二条 公司董事、监事和高级管理人员在买卖本公司股票及其衍生品种 前，应知悉《公司法》《证券法》等法律、法规、规范性文件关于内幕交易、短 线交易、操纵市场等禁止行为的规定，不得进行违法违规的交易。 第三条 公司董事、监事和高级管理人员所持公司股份，是指登记在其名 下和利用他人账户持有的所有本公司股份；公司董事、监事和高级管理人员从事 融资融券交易的，还包括记载在其信用账户内的本公司股份；公司董事、监事、 高级管理人员委托他人代行买卖股票，视作本人所为，也应遵守本制度并履行相 关 ...

Group 1: Company Overview - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is listed under stock code 603392 and is known for its focus on biological pharmaceuticals [1] - The company held an investor relations activity on September 24, 2024, attended by various financial institutions including CITIC Securities and CICC [1] Group 2: Financial Management - The company plans to use up to 4.5 billion CNY of idle funds for cash management, investing in low-risk financial products [3] - Future share buyback or management increase plans will be considered based on actual needs and will comply with legal disclosure requirements [2] Group 3: Business Development - The company is enhancing its IVD (In Vitro Diagnostics) business by expanding product offerings and optimizing existing projects to meet clinical needs [3] - Future strategies include accelerating innovation in IVD products and expanding reagent menus, particularly for cancer and elderly disease markers [3] Group 4: Market Expansion - The company is focusing on domestic vaccine sales strategies and strengthening its sales team to penetrate deeper into the market [4] - Internationally, the company is pursuing product registration and collaborating with organizations like GAVI to explore new growth opportunities [4] Group 5: Collaboration and Partnerships - The termination of the collaboration agreement with GSK was a mutual decision, with the company not privy to GSK's internal requirements for clinical trials [4]

证券代码：603392 证券简称：万泰生物 公告编号：2024-059 北京万泰生物药业股份有限公司 关于参加医药生物行业上市公司 2024 年度 集中路演活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步展现公司经营发展情况，加强与广大投资者的互动交流，促进提升 公司质量和投资价值，北京万泰生物药业股份有限公司（以下简称"公司"）将 参加在深圳证券交易所上市大厅举办的"医药生物行业上市公司 2024 年度集中 路演"活动，现将相关事项公告如下： 二、投资者参与方式 1、本次活动投资者可在 2024 年 9 月 20 日(星期五)下午 14:00-17:00，登录 上海证券交易所上证路演中心（http://roadshow.sseinfo.com/），参与线上互动交 流。 2、为广泛听取投资者的意见和建议，提升交流的针对性，投资者可于 2024 年 9 月 19 日(星期四) 下午 16:00 前通过公司邮箱 wtzqb@ystwt.com 进行提问。 公司将在集中路演活动上对投资者普遍关注的问题进行回答。 ...

证券代码：603392 证券简称：万泰生物 公告编号：2024-058 北京万泰生物药业股份有限公司 关于股份回购实施结果暨股份变动的公告 （四）本次股份回购方案的实施对公司的影响 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | | | | | 2023/8/29，本次回购方案由时任公司董事长兼总经理邱 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 子欣先生提议。 | | | | | | | | 回购方案实施期限 | 年 2023 9 | 月 13 | 日~2024 | | 年 9 | 月 | 日 12 | | 预计回购金额 | 20,000 万元~40,000 | | | 万元 | | | | | 回购价格上限 | 98.00 元/股 | | | | | | | | 回购用途 | √减少注册资本 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 实际回购股数 | ...

重要内容提示： | 回购方案首次披露日 | 2023/8/29，本次回购方案由时任公司董事长兼总经理邱 | | | | --- | --- | --- | --- | | | 子欣先生提议。 | | | | 回购方案实施期限 | 2023 年 9 日~2024 年 月 | 月 13 | 9 12 日 | | 预计回购金额 | 万元 20,000 万元~40,000 | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 288.0385 | 万股 | | | 累计已回购股数占总 股本比例 | 0.2271% | | | | 累计已回购金额 | 18,612.53 | 万元 | | | 实际回购价格区间 | 45.55 元/股~74.48 元/股 | | | 一、 回购股份的基本情况 证券代码：603392 证券简称：万泰生物 公告编号：2024-057 北京万泰生物药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不 ...

Investment Rating - The investment rating for the company is "Buy" [12]. Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2024, with revenue at 1.366 billion yuan, down 67.19% year-on-year, and net profit at 260 million yuan, down 84.70% year-on-year [2][6]. - The company is advancing its product pipeline, including the acceptance of the application for the nine-valent HPV vaccine, which is expected to enhance its market position [5][6]. - The company has achieved market access for its bivalent HPV vaccine in 18 countries and is actively pursuing further international market development [6]. Financial Performance Summary - For 2024, the company expects revenues of 2.715 billion yuan, a decrease of 50.74% year-on-year, with a projected net profit of 558 million yuan, down 55.31% year-on-year [7]. - The company’s earnings per share (EPS) for 2024 is estimated at 0.44 yuan, with a compound annual growth rate (CAGR) of 46.61% from 2024 to 2026 [7]. - The company’s financial metrics indicate a significant drop in profitability, with EBITDA projected to be 1.199 billion yuan in 2024, down from 1.556 billion yuan in 2023 [4][7]. Market Position and Product Development - The company is the first domestic supplier of HPV vaccines, which positions it favorably in the market [7]. - The nine-valent HPV vaccine has completed key clinical trials and is on track for commercialization, with priority review status granted by the National Medical Products Administration [6][7]. - The company is also developing a 20-valent pneumonia conjugate vaccine and a new freeze-dried varicella vaccine, indicating a robust pipeline of products [6].

证券代码：603392 证券简称：万泰生物 公告编号：2024-056 北京万泰生物药业股份有限公司 关于公司九价 HPV 疫苗上市许可申请 获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司(以下简称"公司")全资子公司厦门 万泰沧海生物技术有限公司（以下简称"万泰沧海"）收到国家药品监督管理局 （以下简称"国家药监局"）药品审评中心下发的万泰沧海与厦门大学合作研发 的"重组人乳头瘤病毒 6/11/16/18/31/33/45/52/58 型九价疫苗（大肠埃希菌）（以 下简称"九价 HPV 疫苗"）"上市许可申请的《受理通知书》。有关详情如下： 一、《受理通知书》的主要信息 九价 HPV 疫苗顺利获批上市，将有利于公司 HPV 疫苗的推广和使用，丰富 公司产品线，进一步增强公司的核心竞争力，为公司持续稳健发展奠定坚实基础。 四、风险提示 1、根据国家关于疫苗注册管理的相关规定，九价 HPV 疫苗上市注册申请获 得受理后，需经过综合审评、生产现场核查等程序，注册申请的最终获批及获 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 15%[2]. - The company's revenue for the first half of 2024 was CNY 1,366,045,101.74, a decrease of 67.19% compared to CNY 4,163,641,154.70 in the same period last year[20]. - Net profit attributable to shareholders was CNY 260,480,462.16, down 84.70% from CNY 1,702,358,148.94 year-on-year[20]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 63,520,625.14, a decline of 96.09% compared to CNY 1,623,174,034.86 in the previous year[20]. - Net cash flow from operating activities was CNY 128,547,517.42, a decrease of 22.62% from CNY 166,121,691.21 in the same period last year[20]. - The basic earnings per share decreased by 84.33% to 0.21 CNY compared to the same period last year[21]. - The diluted earnings per share also decreased by 84.33% to 0.21 CNY compared to the same period last year[21]. - The company's net profit for the first half of 2024 was CNY 384,847,977.73, a decrease from CNY 1,482,638,184.97 in the same period of 2023, representing a decline of approximately 74%[177]. - Total operating revenue for the first half of 2024 was CNY 1,366,045,101.74, a decrease of 67.2% compared to CNY 4,163,641,154.70 in the same period of 2023[172]. - Total operating costs for the first half of 2024 were CNY 1,289,398,978.35, down 42.5% from CNY 2,242,973,767.22 in the first half of 2023[172]. Market and User Growth - User data indicates a growth in the active user base by 20% compared to the same period last year, reaching 5 million users[2]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2024, reflecting a growth target of 10%[2]. - Market expansion efforts have led to a 30% increase in sales in international markets, particularly in Southeast Asia[2]. - Strategic partnerships with healthcare providers have been established, aiming to increase market penetration by 15% over the next year[2]. Research and Development - The company is investing RMB 300 million in R&D for new technologies aimed at enhancing diagnostic accuracy and speed[2]. - The company has established a comprehensive vaccine R&D technology platform, including various advanced technologies such as high-throughput expression screening and mRNA vaccine development, supporting its strategic goal to become a leader in the global vaccine industry[59]. - The company is focusing on expanding its market presence in the IVD sector, which is crucial for enhancing diagnostic accuracy and efficiency[26]. - The company has developed a hepatitis C diagnostic test that improves sensitivity by 8-10 times, significantly reducing the window period and transmission risk[34]. - The company has established multiple diagnostic technology platforms, including automated biochemical immunoassay instruments and PCR detection technology, successfully launching various in vitro diagnostic reagent products[50]. Product Development and Innovation - New product launches in the diagnostics segment contributed to a 25% increase in sales volume during the reporting period[2]. - The company has a comprehensive product range in the in vitro diagnostics field, including various testing reagents and automated diagnostic instruments[32]. - The company has achieved significant milestones in HIV diagnostics, including the launch of the world's first urine rapid test for HIV in 2019[33]. - The company has developed a new COVID-19 antigen test with a detection time of 15 minutes, achieving high sensitivity and specificity, and has received certifications from multiple international organizations, exporting to over 40 countries[35]. - The company has launched a new calcitonin product, enhancing its thyroid cancer detection portfolio, which is expected to drive growth in its thyroid function series products[35]. Financial Management and Investments - The company reported a total investment of 504,052.30 million RMB in significant non-equity projects, with an actual investment of 36,124.29 million RMB during the reporting period[91]. - The company has ongoing projects including the expansion of the nine-valent cervical cancer vaccine with a total project amount of 124,918.85 million RMB and actual investment of 10,686.76 million RMB[91]. - The company has a cash management balance of RMB 5.00 billion as of the end of the reporting period, with an authorized limit of RMB 20.00 billion[152]. - The company has a total of 1,298,942,359.86 RMB in other payables, which represents a decrease of 29.20% from the previous period[89]. - The company has received milestone payments totaling approximately 1.34 billion euros (about 1 billion RMB) from GSK for the development of a new cervical cancer vaccine[146]. Corporate Governance and Management Changes - The company appointed Jiang Zhiming as the new General Manager in January 2024, following the resignation of the previous General Manager Qiu Zixin, who will continue as Chairman[104]. - The company held its annual shareholders' meeting on April 19, 2024, to approve the election of the new board and supervisory committee[106]. - The company has undergone significant changes in its board and management structure, with multiple new appointments and resignations[105]. Environmental and Social Responsibility - The company has achieved ISO14001 and ISO50001 certifications, enhancing its environmental management performance[119]. - The company donated HPV vaccines worth 34.8 million yuan during the reporting period as part of its social responsibility initiatives[123]. - The company has implemented online monitoring for wastewater discharge at both facilities, with real-time data uploaded to regulatory platforms[118]. - The company has committed to resource reuse and recycling for large volumes of solid waste generated[120]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[2]. - The company faces financial risks, including potential asset losses from R&D failures and accounts receivable risks due to budget constraints at customer organizations[101]. - The domestic in vitro diagnostic industry is experiencing intense competition, with many companies entering various segments, leading to a trend of product homogenization[98].